Immunotherapies Flashcards Preview

Pathology > Immunotherapies > Flashcards

Flashcards in Immunotherapies Deck (20)
Loading flashcards...
1

A letter AND a number

Psoriasis

A. Inhibit RANK ligand
B. Inhibit IL12/23 or TNF alpha
C. Inhibit TNF alpha
D. Inhibit IL6 or TNF alpha

1. Ustekinumab or etanercept
2. Infliximab
3. Denosumab
4. Adalimumab or tocilizumab

Inhibit IL12/23 or TNF alpha

Ustekinumab or etanercept

2

A letter AND a number

Rheumatoid arthritis

A. Inhibit RANK ligand
B. Inhibit IL12/23 or TNF alpha
C. Inhibit TNF alpha
D. Inhibit IL6 or TNF alpha

1. Ustekinumab or etanercept
2. Infliximab
3. Denosumab
4. Adalimumab or tocilizumab

D. Inhibit IL6 or TNF alpha

4. Adalimumab or tocilizumab

3

A letter AND a number

Osteoporosis

A. Inhibit RANK ligand
B. Inhibit IL12/23 or TNF alpha
C. Inhibit TNF alpha
D. Inhibit IL6 or TNF alpha

1. Ustekinumab or etanercept
2. Infliximab
3. Denosumab
4. Adalimumab or tocilizumab

A. Inhibit RANK ligand
3. Denosumab

4

A letter AND a number

Crohn’s disease

A. Inhibit RANK ligand
B. Inhibit IL12/23 or TNF alpha
C. Inhibit TNF alpha
D. Inhibit IL6 or TNF alpha

1. Ustekinumab or etanercept
2. Infliximab
3. Denosumab
4. Adalimumab or tocilizumab

C. Inhibit TNF alpha
2. Infliximab

5

Basiliximab (Anti-IL2 receptor)


A. Inhibits T cell migration but may only be used in highly active remitting/relapsing MS

B. Inhibits T cell activation and is effective in rheumatoid arthritis

C. Depletes B cells and is effective in treatment of B cell lymphomas and rheumatoid arthritis

D. Inhibits function of lymphoid and myeloid cells and used in management of rheumatoid arthritis

E. Antibody specific for CD25 which inhibits T cell activation and is used to prevent rejection

E. Antibody specific for CD25 which inhibits T cell activation and is used to prevent rejection

6

Abatacept (CTLA4-Ig fusion protein)

A. Inhibits T cell migration but may only be used in highly active remitting/relapsing MS

B. Inhibits T cell activation and is effective in rheumatoid arthritis

C. Depletes B cells and is effective in treatment of B cell lymphomas and rheumatoid arthritis

D. Inhibits function of lymphoid and myeloid cells and used in management of rheumatoid arthritis

E. Antibody specific for CD25 which inhibits T cell activation and is used to prevent rejection

B. Inhibits T cell activation and is effective in rheumatoid arthritis

7

Rituximab (Anti-CD20)

A. Inhibits T cell migration but may only be used in highly active remitting/relapsing MS

B. Inhibits T cell activation and is effective in rheumatoid arthritis

C. Depletes B cells and is effective in treatment of B cell lymphomas and rheumatoid arthritis

D. Inhibits function of lymphoid and myeloid cells and used in management of rheumatoid arthritis

E. Antibody specific for CD25 which inhibits T cell activation and is used to prevent rejection

C. Depletes B cells and is effective in treatment of B cell lymphomas and rheumatoid arthritis

8

Natalizumab (Anti- a4 integrin)


A. Inhibits T cell migration but may only be used in highly active remitting/relapsing MS

B. Inhibits T cell activation and is effective in rheumatoid arthritis

C. Depletes B cells and is effective in treatment of B cell lymphomas and rheumatoid arthritis

D. Inhibits function of lymphoid and myeloid cells and used in management of rheumatoid arthritis

E. Antibody specific for CD25 which inhibits T cell activation and is used to prevent rejection

A. Inhibits T cell migration but may only be used in highly active remitting/relapsing MS

9

Tocilizumab (Anti-IL6 receptor)

A. Inhibits T cell migration but may only be used in highly active remitting/relapsing MS

B. Inhibits T cell activation and is effective in rheumatoid arthritis

C. Depletes B cells and is effective in treatment of B cell lymphomas and rheumatoid arthritis

D. Inhibits function of lymphoid and myeloid cells and used in management of rheumatoid arthritis

E. Antibody specific for CD25 which inhibits T cell activation and is used to prevent rejection

D. Inhibits function of lymphoid and myeloid cells and used in management of rheumatoid arthritis

10

Cyclophosphamide

A. Osteoporosis
B. Infertility
C. Progressive multifocal leukoencephalopathy
D. Neutropenia particularly if TPMT low
E. Hypertension

B. Infertility

11

Prednisolone

A. Osteoporosis
B. Infertility
C. Progressive multifocal leukoencephalopathy
D. Neutropenia particularly if TPMT low
E. Hypertension

A. Osteoporosis

12

Azathioprine

A. Osteoporosis
B. Infertility
C. Progressive multifocal leukoencephalopathy
D. Neutropenia particularly if TPMT low
E. Hypertension

D. Neutropenia particularly if TPMT low

13

Cyclosporin

A. Osteoporosis
B. Infertility
C. Progressive multifocal leukoencephalopathy
D. Neutropenia particularly if TPMT low
E. Hypertension

E. Hypertension

14

Mycophenolate mofetil

A. Osteoporosis
B. Infertility
C. Progressive multifocal leukoencephalopathy
D. Neutropenia particularly if TPMT low
E. Hypertension

C. Progressive multifocal leukoencephalopathy

15

IFN alpha

A. Post-transplant lymphoproliferative disorder
B. Part of treatment for Hepatitis C C. X linked hyper IgM syndrome D. X linked SCID E. Chronic granulomatous disease
F. Immunosuppressed seronegative individual after chicken pox exposure

B. Part of treatment for Hepatitis C

16

Bone marrow transplantation

A. Post-transplant lymphoproliferative disorder
B. Part of treatment for Hepatitis C C. X linked hyper IgM syndrome D. X linked SCID E. Chronic granulomatous disease
F. Immunosuppressed seronegative individual after chicken pox exposure

D. X linked SCID

17

IFN gamma

A. Post-transplant lymphoproliferative disorder
B. Part of treatment for Hepatitis C C. X linked hyper IgM syndrome D. X linked SCID E. Chronic granulomatous disease
F. Immunosuppressed seronegative individual after chicken pox exposure

E. Chronic granulomatous disease

18

EBV-specific CD8 T cells

A. Post-transplant lymphoproliferative disorder
B. Part of treatment for Hepatitis C C. X linked hyper IgM syndrome D. X linked SCID E. Chronic granulomatous disease
F. Immunosuppressed seronegative individual after chicken pox exposure

. Post-transplant lymphoproliferative disorder

19

Human normal immunoglobulin

A. Post-transplant lymphoproliferative disorder
B. Part of treatment for Hepatitis C C. X linked hyper IgM syndrome D. X linked SCID E. Chronic granulomatous disease
F. Immunosuppressed seronegative individual after chicken pox exposure

C. X linked hyper IgM syndrome

20

Varicella zoster immunoglobulin

A. Post-transplant lymphoproliferative disorder
B. Part of treatment for Hepatitis C C. X linked hyper IgM syndrome D. X linked SCID E. Chronic granulomatous disease
F. Immunosuppressed seronegative individual after chicken pox exposure

F. Immunosuppressed seronegative individual after chicken pox exposure